BioXcel Therapeutics, Inc. | Update investor relations page to protect shareholder securities against short selling at BioXcel Therapeutics, Inc.

Status
Omitted
AGM date
Resolution details
Company ticker
BTAI
Lead filer
Individual
Resolution ask
Other ask
ESG theme
  • Governance
ESG sub-theme
  • Shareholder rights
Type of vote
Shareholder proposal
Filer type
Shareholder
Company HQ country
United States
Resolved clause
BioXcel Therapeutics should add a disclosure to the investor relations page on our website letting our shareholders know how they can protect their securities against short selling. This new disclosure should include 1) holding "shares" in a cash account at their brokerage firm instead of a margin account, 2) opting out of any securities lending programs, which should stop their broker from lending their "shares," 3) transferring their shares from their broker to their own name with our transfer agent (American Stock Transfer). This is known as "DRS". In addition, once this new disclosure is published on our website, we should file an 8-K to inform the public that the new disclosure has been added.

DISCLAIMER: By including a shareholder resolution or management proposal in this database, neither the PRI nor the sponsor of the resolution or proposal is seeking authority to act as proxy for any shareholder; shareholders should vote their proxies in accordance with their own policies and requirements.

Any voting recommendations set forth in the descriptions of the resolutions and management proposals included in this database are made by the sponsors of those resolutions and proposals, and do not represent the views of the PRI.

Information on the shareholder resolutions, management proposals and votes in this database have been obtained from sources that are believed to be reliable, but the PRI does not represent that it is accurate, complete, or up-to-date, including information relating to resolutions and management proposals, other signatories’ vote pre-declarations (including voting rationales), or the current status of a resolution or proposal. You should consult companies’ proxy statements for complete information on all matters to be voted on at a meeting.